Medical Technology

@xconomy.com 3 years ago

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

@xconomy.com 4 years ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 4 years ago

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

@xconomy.com 4 years ago

After First Look at House Drug Plan, Stocks Rise Slightly

@xconomy.com 4 years ago

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

@xconomy.com 4 years ago

New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)

@xconomy.com 4 years ago

Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More

@xconomy.com 4 years ago

Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?

@xconomy.com 4 years ago

At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments

@xconomy.com 5 years ago

Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More

@xconomy.com 5 years ago

Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More

@xconomy.com 5 years ago

Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More

@xconomy.com 5 years ago

Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away

@xconomy.com 5 years ago

Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More

@xconomy.com 5 years ago

Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More

@xconomy.com 5 years ago

Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More

@xconomy.com 5 years ago

Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More

@xconomy.com 5 years ago

Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines

@xconomy.com 5 years ago

Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details